Xilio to Present Phase 1C Data for XTX101 with Atezolizumab at SITC Annual Meeting

Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company based in Waltham, Massachusetts, has announced initial data from its Phase 1C dose escalation study of XTX101 (vilastobart) in combination with atezolizumab. This information will be presented at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, which will be held in Houston, Texas, from November 6-10, 2024. The details of the poster presentation are as follows:

Title: Phase 1/2 Study of Vilastobart (formerly XTX101), a Tumor-Activated, Fc-enhanced Anti-CTLA-4 Monoclonal Antibody, in Combination with Atezolizumab in Patients with Advanced Solid Tumors
Abstract Number: 1455
Presentation Date: Friday, Nov. 8, 2024
Poster Hall Hours: 9 a.m. – 7 p.m. CST
Location: George R. Brown Convention Center

Vilastobart (XTX101) is an investigational tumor-activated, Fc-enhanced, high-affinity binding anti-CTLA-4 monoclonal antibody. It is designed to block CTLA-4 and to deplete regulatory T cells when activated in the tumor microenvironment (TME). In 2023, Xilio Therapeutics entered into a co-funded clinical trial collaboration with Roche to evaluate vilastobart in combination with atezolizumab (Tecentriq®) in a multi-center, open-label Phase 1/2 clinical trial. Currently, Xilio is evaluating the safety of the combination in a Phase 1C dose escalation in patients with advanced solid tumors. The safety and efficacy of the combination are also being evaluated in a Phase 2 clinical trial in patients with microsatellite stable colorectal cancer (MSS CRC), including those with and without liver metastases.

For more information on the trial, refer to NCT04896697 on www.clinicaltrials.gov.

Xilio Therapeutics is focused on discovering and developing tumor-activated immuno-oncology therapies aimed at significantly improving outcomes for cancer patients without the systemic side effects associated with current immuno-oncology treatments. The company employs its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical immuno-oncology molecules. These molecules are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment. The pipeline includes tumor-activated cytokines, antibodies, bispecifics, and immune cell engagers.

For more information about Xilio Therapeutics and its research, visit their website or follow them on LinkedIn (Xilio Therapeutics, Inc.).

Vilastobart (XTX101) is part of Xilio Therapeutics' innovative approach to cancer treatment, targeting the tumor microenvironment to enhance efficacy and reduce systemic side effects. The ongoing clinical trials with vilastobart aim to provide new insights into its potential as a combination therapy with atezolizumab.

Xilio's collaboration with Roche underscores the potential of combining their proprietary tumor-activated therapies with established immuno-oncology treatments like atezolizumab. This partnership is crucial for advancing clinical trials and potentially bringing new therapeutic options to patients with advanced solid tumors.

The presentation at the SITC Annual Meeting will provide an important platform for showcasing the initial data from the Phase 1C dose escalation study. This data is expected to offer valuable insights into the safety and potential efficacy of vilastobart in combination with atezolizumab, contributing to the broader goal of developing more effective cancer treatments.

Xilio Therapeutics remains committed to advancing its pipeline of tumor-activated therapies, with the ultimate goal of improving the lives of people living with cancer. The company's innovative approach and strategic collaborations position it at the forefront of immuno-oncology research and development.